(Booth 7032) Dutch software firm Medis of Leiden will tout two software products, one for analyzing MRI studies of the brain and another for assessing vulnerable plaque.
QBrain is designed to help clinicians diagnose and monitor conditions such as multiple sclerosis (MS) and Alzheimer's disease by enabling them to compare lesions in follow-up studies to original scans. The software supports the calculation of volumes and volume changes to help users track changes in the brain over time.
QBrain has been cleared by the U.S. Food and Drug Administration, and is expected to be available in the fourth quarter of 2007 in the U.S. and internationally.
QPlaque MR is designed to identify and quantify vulnerable plaque in atherosclerosis patients by postprocessing multispectral MR images. It enables cardiologists and radiologists to measure thickness, area, and volume of diseased vessel walls and plaque components. This can aid medical specialists in detecting plaque composition and high-risk plaques before they rupture, according to the company.
QPlaque MR provides tools for semiautomatically determining the vessel boundaries, lumen, and plaque components, calculating vessel wall and plaque volumes, and measuring the thickness of the vessel wall and the fibrous cap. QPlaque MR also provides advanced editing tools, and automatic registration of different MR sequences.
QPlaque MR is expected to be available on the U.S. market and in other countries worldwide in the first quarter of 2008.
